Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter F Lebowitz

Showing results (11-20 of 17) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 17 results.
Journal of Clinical Pharmacology|February 4, 2010
Ketoconazole and rifampin significantly affect the pharmacokinetics, but not the safety or QTc interval, of casopitant, a neurokinin-1 receptor antagonistBrendan M Johnson, Laurel M Adams, Ke Zhang, et al.
Investigational New Drugs|December 29, 2010
Effect of hepatic or renal impairment on the pharmacokinetics of casopitant, a NK-1 receptor antagonistJohn W Bauman, Joyce M Antal, Laurel M Adams, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 21, 2008
Phase I dose escalation and pharmacokinetic study of lapatinib in combination with trastuzumab in patients with advanced ErbB2-positive breast cancerAnna Maria Storniolo, Mark D Pegram, Beth Overmoyer, et al.
International Journal of Radiation Oncology, Biology, Physics|July 12, 2005
Inhibition of nuclear factor-kappaB and target genes during combined therapy with proteasome inhibitor bortezomib and reirradiation in patients with recurrent head-and-neck squamous cell carcinomaCarter Van Waes, Angela A Chang, Peter F Lebowitz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 9, 2013
Tumor genetic analyses of patients with metastatic melanoma treated with the BRAF inhibitor dabrafenib (GSK2118436)Katherine L Nathanson, Anne-Marie Martin, Bradley Wubbenhorst, et al.
Med (New York, N.Y.)|October 18, 2022
Enhanced delivery of antibodies across the blood-brain barrier via TEMs with inherent receptor-mediated phagocytosisSuzanne Edavettal, Pilar Cejudo-Martin, Bidisha Dasgupta, et al.
The Lancet. Oncology|July 19, 2012
Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trialGerald S Falchook, Karl D Lewis, Jeffrey R Infante, et al.
Pageof 2

Showing results (11-20 of 17) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 17 results.
Journal of Clinical Pharmacology|February 4, 2010
Ketoconazole and rifampin significantly affect the pharmacokinetics, but not the safety or QTc interval, of casopitant, a neurokinin-1 receptor antagonistBrendan M Johnson, Laurel M Adams, Ke Zhang, et al.
Investigational New Drugs|December 29, 2010
Effect of hepatic or renal impairment on the pharmacokinetics of casopitant, a NK-1 receptor antagonistJohn W Bauman, Joyce M Antal, Laurel M Adams, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 21, 2008
Phase I dose escalation and pharmacokinetic study of lapatinib in combination with trastuzumab in patients with advanced ErbB2-positive breast cancerAnna Maria Storniolo, Mark D Pegram, Beth Overmoyer, et al.
International Journal of Radiation Oncology, Biology, Physics|July 12, 2005
Inhibition of nuclear factor-kappaB and target genes during combined therapy with proteasome inhibitor bortezomib and reirradiation in patients with recurrent head-and-neck squamous cell carcinomaCarter Van Waes, Angela A Chang, Peter F Lebowitz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 9, 2013
Tumor genetic analyses of patients with metastatic melanoma treated with the BRAF inhibitor dabrafenib (GSK2118436)Katherine L Nathanson, Anne-Marie Martin, Bradley Wubbenhorst, et al.
Med (New York, N.Y.)|October 18, 2022
Enhanced delivery of antibodies across the blood-brain barrier via TEMs with inherent receptor-mediated phagocytosisSuzanne Edavettal, Pilar Cejudo-Martin, Bidisha Dasgupta, et al.
The Lancet. Oncology|July 19, 2012
Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trialGerald S Falchook, Karl D Lewis, Jeffrey R Infante, et al.
Pageof 2